Boule Diagnostics AB (OSTO:BOUL)

Q1 2025 Boule Diagnostics AB Earnings Call Transcript

Apr 28, 2025 / 08:00 AM GMT

Release Date Price: kr8.3 (+1.75%)

Transcript

Key Points

Positve

Boule Diagnostics AB (OSTO:BOUL) reported a significant improvement in operating margin, reaching 15.1%, up from 12.9% in the previous year.
The company achieved 7% organic growth in its OEM business, extending and expanding a supply agreement with a leading global IVD company.
Boule Diagnostics AB (OSTO:BOUL) successfully reduced annual R&D spending by 50% following the closure of the BM 950 project.
The company signed a new and expanded lease agreement for a second manufacturing site in Sweden, optimizing operations and reducing costs.
Boule Diagnostics AB (OSTO:BOUL) is focusing on strategic growth by onboarding new sales managers in Southeast Asia and the US to enhance market presence.

Negative

The company experienced a 25.1% negative organic growth in Q1 2025, primarily due to delayed shipments and unfavorable year-on-year comparisons.
Geopolitical instability and US tariff policy uncertainties led to restricted access to US dollars in core markets, causing delayed payments and shipments.
Sales in Southeast Asia and India were down, with India transitioning to a license manufacturing model impacting top-line revenue.
The closure of the BM 950 project resulted in a one-time cost of 18.5 million SEK, impacting financial performance.
Cash flow from operating activities was negatively impacted by severance payments, increased inventory, and receivables, with available liquidity at 38 million SEK.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BOUL.ST - Boule Diagnostics AB
Q1 2025 Boule Diagnostics AB Earnings Call
Apr 28, 2025 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everybody and welcome to the 1st quarter's earnings call football diagnostics.

I'm Jorge Lambe, CEO of Boo Diagnostics, and with me, I have our CEO Torba Nielsen.

After our presentation, we will open up for questions, but please also feel free to type questions in the chat field. With that, I'm handing over to our CEO Thorba Nielsen.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yeah, thanks, Holger and good morning to everyone and thank you for joining this Q1 earnings fall for 2025.

We'll begin by taking a look at the highlights of the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.